
    
      1. Design: Single dose, randomized, two-period, two-treatment, two- sequence crossover
           study under non-fasting conditions comparing equal doses of the test and reference
           products.

        2. Interval between dosing periods: At least one week

        3. Period of confinement: From at least 10.5 hours before dosing until after the 36 hour
           blood collection each period. Subjects will return to the clinic for subsequent blood
           collations.

      A total of thirty six (36) subjects were enrolled in this study; 33 completed the study.
    
  